Catherine has earned her reputation as a biopharmaceutical thought leader and gained the trust of C-Suite and Board Members of life science companies having spent more than 25 years engaging with them. She offers Biopharma clients a unique perspective from her diverse experience, having been a public equity investor for one of the world’s largest asset managers, an industry executive, a top-ranked sell-side analyst, and a clinician at a large university medical center. Catherine often engages with Biotech companies early in their development and leverages her big Pharma relationships to enable productive connections.

Ms. Arnold’s recent life science transactions and advisory include:

• The $40bn acquisition by AstraZeneca of Alexion

• $12.5bn sale of Biohaven to Pfizer with simultaneous spin of neuroscience assets into a new publicly traded company

• $11.5bn sale of Acceleron to Merck

• $6.7bn acquisition of Arena Pharmaceuticals by Pfizer

• Sanofi’s strategic review and bid for Horizon Therapeutics, ultimately acquired by Amgen for $28bn

• Pfizer’s spin out of select autoimmune assets

• $10bn sale of Verona Pharma plc to Merck

• $3.9bn sale of SpringWorks Therapeutics to Merck KGgA

• $924mn sale of Revance Therapeutics to Crown Laboratories

• Up to $900mn sale of Emalex to Teva

Prior to joining Centerview, Catherine served as Managing Director, Portfolio Manager and Biopharmaceuticals Global Industry Analyst at Wellington Management in Boston, Massachusetts. In this role she regularly engaged with healthcare executives and boards on strategy, industry dynamics, capital markets and science, and served on the firm’s Investment Stewardship Committee. Prior to Wellington, Catherine spent more than a decade as a top-rated sell-side analyst at Credit Suisse and Sanford C. Bernstein & Co., covering the biopharmaceutical sector. Earlier in her career, Ms. Arnold served as the Director of Business Development and Strategic Planning at Hoffman-La Roche Pharmaceuticals and as a Senior Associate in the Biopharma Management Consulting Practice at Booz Allen Hamilton. Ms. Arnold previously served on the Advisory Board for the FDA Modernization Task Force, a member of the Health Forum of the Aspen Institute and was a Director of the National Board of the Cancer Support Community. She has contributed to Columbia Business School’s Healthcare and Pharmaceutical Management Program and serves as a Series Guest Lecturer at Harvard Business School.